Comparison between two treatment protocols with recombinant Human Erythropoietin (rHuEpo) in the treatment of late anemia in neonates with Rh-Isoimmunization

A.A. Zuppa, G. Alighieri, A. Fracchiolla, P. Catenazzi, A. D’Antuono, R. Riccardi, M. Cavani, C. Romagnoli
  • A.A. Zuppa
    Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy | zuppaaa@rm.unicatt.it
  • G. Alighieri
    Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy
  • A. Fracchiolla
    Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy
  • P. Catenazzi
    Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy
  • A. D’Antuono
    Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy
  • R. Riccardi
    Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy
  • M. Cavani
    Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy
  • C. Romagnoli
    Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy

Abstract

Objectve. The Rh-hemolytic disease can lead to a late anemia by hemolytic and hyporigenerative mechanism. We compared the effectiveness of rHuEPO in two care protocols that differ for doses of rHuEPO administrated and for timing of administration. Methods. A cohort of 14 neonates was investigated. The neonates were treated with two different protocols. Protocol A: a dose of 200 U/kg/day of rHuEpo administered subcutaneously starting from the end of the second week of life; Protocol B: a dose of 400 U/kg/day of rHuEpo administered subcutaneously starting from the end of the first week of life. Results. The hematocrit values in the protocol A group decreased during treatment (32,5% vs 25,2%), whereas the hematocrit value in protocol B group remained almost stable (38,7% vs 42,8%). The mean numbers of platelets remained stable in both groups while neutrophils increased in protocol A group and decreased in protocol B (p<0,05). Reticulocyte count increased during treatment in both groups, although only in protocol B group it was statistically significative (p<0,05). Conclusions. Our results suggest a similar efficacy between the two treatment protocols. Increasing doses of rHuEPO do not seem enhancing their effectiveness and the incidence of side effects.

Keywords

rHuEpo, late anemia, Rh isoimmunization, newborn

Full Text:

PDF
Submitted: 2014-11-18 15:25:30
Published: 2012-08-31 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
367

Views:
PDF
301

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2012 A.A. Zuppa, G. Alighieri, A. Fracchiolla, P. Catenazzi, A. D’Antuono, R. Riccardi, M. Cavani, C. Romagnoli

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185